Trial Profile
A Phase I/II Study of Pazopanib in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme After Surgery and RT-CT
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PAZOGLIO
- 28 Feb 2024 The updated results (n=20) of the phase I presented at the ESMO Targeted Anticancer Therapies Congress 2024
- 28 Feb 2024 The phase II part is currently enrolling, according to results presented at the ESMO Targeted Anticancer Therapies Congress 2024
- 06 Jun 2023 Results (n=20) assessing safety and efficacy of pazopanib and temozolomide in patients with newly diagnosed and resected glioblastoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology